RxDoctor Payments Data

Jeannette Guzman

Family · New York, NYNPI 1982957569

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 496 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,694in general payments, 2019–2025

Across 496 payments — averaging $41.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$2K
  • AbbVie$2K
  • Esperion Therapeutics, Inc.$1K
  • Amgen$1K
  • Johnson & Johnson$1K
  • plus $10K from 38 others

What the payments were for

  • Food & beverage$20,602100%
  • Education$920%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,694 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide234$236,017
FarxigaDapagliflozin Propanediol184$172,825
JardianceEmpagliflozin170$172,102
RybelsusSemaglutide91$101,424
KerendiaFinerenone101$72,173
ZenpepLipase/Protease/Amylase18$69,645
VascepaIcosapent Ethyl102$63,582
LinzessLinaclotide93$49,427
TrulicityDulaglutide31$35,188
JanumetSitagliptin Phos/Metformin Hcl19$27,127
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$24,638
SynjardyEmpagliflozin/Metformin Hcl22$22,650
JanuviaSitagliptin Phosphate14$18,141
Xigduo XrDapaglifloz Propaned/Metformin18$13,202
EliquisApixaban16$13,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,314$337,441325 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,666$197,463216 claims
Boehringer IngelheimJardiance, Synjardy$574$194,753192 claims
BayerKerendia$824$72,173101 claims
Aimmune Therapeutics, Inc.Zenpep$250$69,64518 claims
MerckJanumet, Januvia, Janumet Xr$20$52,77447 claims
AbbVieLinzess$2,001$49,42793 claims
Lilly USA, LLCTrulicity$246$35,18831 claims
PfizerEliquis$224$13,13516 claims
GSKBreo Ellipta$833$5,63215 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$96$5,33416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →